Key Points
- Insider sale: Merck EVP Richard Deluca sold 11,699 shares at an average price of $131.63, generating approximately $1.54 million. He retained 110,167 shares, reducing his position by 9.6%.
- Quarterly performance: Merck reported $16.61 billion in revenue, exceeding estimates of $16.37 billion, while quarterly EPS of $0.13 loss was better than the expected $0.26 loss. Revenue increased 5.1% year over year.
- Outlook and risks: Analysts maintain a “Moderate Buy” consensus with a $135.50 target, supported by recent upgrades and the company’s $0.85 quarterly dividend. However, repeated insider selling, elevated valuation and future Keytruda patent expirations remain risks.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) EVP Richard Deluca sold 11,699 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total value of $1,539,939.37. Following the completion of the transaction, the executive vice president owned 110,167 shares of the company's stock, valued at approximately $14,501,282.21. The trade was a 9.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Merck & Co., Inc. Price Performance
Merck & Co., Inc. stock opened at $133.10 on Thursday. The business's fifty day moving average is $124.94 and its two-hundred day moving average is $119.64. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The firm has a market cap of $328.38 billion, a P/E ratio of 106.48, a P/E/G ratio of 5.62 and a beta of 0.19. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $135.05.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The company had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. During the same period last year, the company posted $2.13 earnings per share. The firm's quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.
Merck & Co., Inc. Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio is presently 272.00%.
Merck & Co., Inc. News Summary
Here are the key news stories impacting Merck & Co., Inc. this week:
- Positive Sentiment: Analyst sentiment improved: Daiwa Securities upgraded Merck to “outperform” and set a $143 price target, while Argus raised its target to $145 and maintained a “buy” rating. These targets imply additional upside from recent trading levels. Daiwa Securities upgrade
- Positive Sentiment: RSV expansion opportunity: The FDA and European Medicines Agency accepted supplemental applications for broader use of ENFLONSIA to prevent RSV in vulnerable young children. The regulatory reviews could expand Merck’s growth beyond oncology and help diversify the portfolio ahead of Keytruda’s future patent expirations. Merck RSV regulatory review article
- Positive Sentiment: Estimates edged higher: Erste Group raised its FY2026 earnings forecast for Merck to $2.75 per share from $2.70, broadly aligning with the $2.76 consensus estimate. The company also recently exceeded quarterly revenue and adjusted earnings expectations, reporting $16.61 billion in revenue.
- Positive Sentiment: Core business remains solid: Keytruda, oncology and animal health supported quarterly growth, while the company continues investing in its pipeline. Merck also declared its regular $0.85 quarterly dividend, equivalent to a $3.40 annualized payout.
- Neutral Sentiment: Vaccine-policy uncertainty: Reports that the administration may seek to split the MMR vaccine into separate shots could create headlines around the broader vaccine market, but experts say the proposal lacks scientific support and is unlikely to advance. MMR vaccine policy article
- Negative Sentiment: Repeated insider selling: EVP Richard R. Deluca sold roughly 45,000 shares across transactions from August 6 through August 12 for approximately $6.7 million. Although he retained a substantial position, the sales may weigh modestly on sentiment.
- Negative Sentiment: Longer-term risks persist: Analysts continue to flag falling estimates, a high valuation and upcoming patent expirations, particularly the eventual loss of Keytruda exclusivity. These issues could limit upside unless Merck’s pipeline and newer products offset the expected revenue pressure.
Analyst Upgrades and Downgrades
MRK has been the subject of a number of research reports. Weiss Ratings lowered shares of Merck & Co., Inc. from a "hold (c)" rating to a "hold (c-)" rating in a report on Tuesday. Argus upped their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a report on Tuesday. Daiwa Securities Group upgraded Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 price objective on the stock in a research report on Wednesday. JPMorgan Chase & Co. lifted their target price on Merck & Co., Inc. from $135.00 to $140.00 and gave the company an "overweight" rating in a research note on Monday, July 13th. Finally, Morgan Stanley boosted their target price on Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 9th. Fifteen analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $135.50.
Get Our Latest Stock Analysis on MRK
Institutional Investors Weigh In On Merck & Co., Inc.
Several institutional investors have recently modified their holdings of the business. Cascade Financial Partners LLC boosted its position in Merck & Co., Inc. by 0.5% during the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company's stock worth $1,895,000 after acquiring an additional 80 shares during the last quarter. Somerset Trust Co raised its holdings in shares of Merck & Co., Inc. by 0.9% in the second quarter. Somerset Trust Co now owns 8,701 shares of the company's stock valued at $1,118,000 after purchasing an additional 81 shares during the last quarter. Stonebridge Financial Group LLC raised its holdings in shares of Merck & Co., Inc. by 0.9% in the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company's stock valued at $1,124,000 after purchasing an additional 81 shares during the last quarter. Stronghold Wealth Management L.L.C. lifted its position in shares of Merck & Co., Inc. by 2.6% in the second quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company's stock worth $416,000 after purchasing an additional 82 shares in the last quarter. Finally, Lederer & Associates Investment Counsel CA lifted its position in shares of Merck & Co., Inc. by 0.9% in the second quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company's stock worth $1,234,000 after purchasing an additional 84 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.
About Merck & Co., Inc.
(
Get Free Report)
Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.
Founded in the late 19th century as the U.S.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
